Atocor (atorvastatin) coated tablets 40 mg. №30

$18.00

Manufacturer: Canada

Category:

Description

Prevention of cardiovascular disease in adults.
For adult patients without clinically pronounced coronary heart disease, but with several risk factors for coronary heart disease, such as age, smoking, arterial hypertension, low HDL or early ischemic heart disease in family history,
reducing the risk of myocardial infarction;
reducing the risk of stroke;
reducing the risk of revascularization and angina.
For adults with type II diabetes mellitus and without clinically pronounced coronary heart disease, but with several risk factors for coronary heart disease, such as retinopathy, albuminuria, tobacco or arterial hypertension, Atocor is indicated for:
reducing the risk of myocardial infarction;
reducing the risk of stroke.
For adult patients with clinically pronounced coronary heart disease, Atocor is indicated for:
reducing the risk of non-lethal myocardial infarction;
reducing the risk of lethal and non-lethal stroke;
reducing the risk of revascularization;
reducing the risk of hospitalization due to congestive heart failure;
reducing the risk of angina.
Hyperlipidemia.
In adult patients.
As a supplement to the diet to reduce high levels of total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides, and to increase HDL cholesterol in patients with primary hypercholesterolemia (heterozygous family and non-family tideipidemia) .
As a supplement to the diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson type IV).
For the treatment of patients with primary dysbitalipoproteinemia (Fredrickson’s type i) in cases where dieting is not effective enough.
To reduce total cholesterol and LDL cholesterol in patients with homozygous familial hypercholesterolemia in addition to other lipid-lowering treatments (eg LDL apheresis), or if such treatments are unavailable.
In children.
As a supplement to a diet to reduce levels of total cholesterol, LDL cholesterol and apolipoprotein B in boys and girls after menstruation at the age of 10 to 17 yEars and Nose with heterozygous familial hypercholesterolemia, if after appropriate diet therapy the results are as follows:
a) LDL cholesterol remains ≥ 190 mg / dL (≥ 4.91 mmol / l) or
b) LDL cholesterol ≥ 160 mg / dL (≥ 4.14 mmol / l) and:
a family history of early cardiovascular disease or
two or more other risk factors for cardiovascular disease are present in a pediatric patient.